Torren Management
RNA icon

Torren Management’s Atrium Therapeutics RNA Stock Holding History

Torren Management’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-4
Closed -$54 – 993
2026
Q2 		$54 Hold
4
– – ﹤0.01% 930
2026
Q1 		$53 Buy
+4
New +$56 ﹤0.01% 962

Other funds holding RNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Torren Management's RNA Position: Q3 2026 in Review

Torren Management sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 4 shares — an estimated $54 sold.

Torren Management first reported a position in RNA in Q1 2026 and held it in 2 quarters. The position peaked at $54 in Q2 2026. 33 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Torren Management reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Torren Management sold 4 Atrium Therapeutics shares in Q3 2026, an estimated $54.
  • Torren Management first reported a position in Atrium Therapeutics in Q1 2026 and held it in 2 quarters.
  • Torren Management's Atrium Therapeutics position peaked at $54 in Q2 2026.
  • 33 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Torren Management's 13F filing for Q3 2026, filed 29 Oct 2026.